FDA approves cryopreserved ReNeuron formulation

Josh White Sharecast | 19 Jun, 2017 12:54 - Updated: 12:54 | | |

Astrazeneca

ReNeuron Group

1.80

17:17 27/06/17
0.00%
0.00
  • 14,698.28
  • -0.91%-134.52
  • Max: 14,841.05
  • Min: 14,684.57
  • Volume: 0
  • MM 200 : n/a
17:24 27/06/17
  • 967.04
  • -0.12%-1.16
  • Max: 970.00
  • Min: 965.19
  • Volume: 0
  • MM 200 : n/a
17:18 27/06/17

Cell-based therapeutics developer ReNeuron Group updated the marker on its cell therapy development programmes targeting degenerative diseases of the retina on Monday, reporting that the US Food and Drug Administration (FDA) had approved the cryopreserved formulation of its human retinal progenitor cell (hRPC) therapeutic candidate.

The AIM-traded firm said that as a result, it had now started treating patients with the formulation in its ongoing US Phase I/II study clinical trial in retinitis pigmentosa (RP) patients.

It said the new proprietary formulation enabled the hRP cells to be frozen for shipping and storage, and easily thawed at the point of clinical use.

That freeze-thaw modality reportedly provided a “greatly enhanced” shelf life for the product, lower prospective cost of goods and the capability to ship the cells for clinical and commercial application anywhere in the world.

The new hRPC formulation had also facilitated an expansion of ReNeuron's clinical programmes in ophthalmology, the board claimed.

As it had previously announced, the company was set to shortly file an application with the FDA to expand the Phase II element of the ongoing Phase I/II clinical trial in RP from six to 20 patients.

The expanded study was designed to provide the “depth and quality” of data that, if positive, would allow subsequent progression to a Phase II/III pivotal study in the indication.

ReNeuron’s board said it also intended to file an application to start a new US Phase II clinical trial later in the year in patients with cone-rod dystrophy, to be conducted alongside the Phase II part of the ongoing RP clinical trial.

“We are delighted that the FDA has approved the use of the cryopreserved formulation of our hRPC retinal cell therapy candidate in our ongoing clinical development programmes,” said ReNeuron CEO Olav Hellebø.

“This is a further significant milestone for ReNeuron, enabling an expansion of our clinical programmes in ophthalmology as well as providing ReNeuron with a significant commercial advantage in terms of prospective cost of goods and ease of use of a retinal disease therapy.”

More news

27 Jun US close: Weak consumer sentiment weighs on markets

Weaker-than-expected readings on consumer confidence weighed on Wall Street throughout Tuesday’s session.

27 Jun Directors dealings: Card Factory chief tops up stake

Card Factory's Karen Hubbard picked up some more shares in the company she leads.

27 Jun Europe close: Jump in single currency after Draghi speaks takes it toll

A more confident tone from European Central Bank chief Mario Draghi and a profit warning from a German auto parts maker combined to send stocks lower across the Continent.

27 Jun US open: Weak data weighs on shares, banks outperform

Weaker than expected readings on consumer confidence weighed on Wall Street early in the session even as investors eyed a speech by Federal Reserve chair Janet Yellen later in the day.

27 Jun FX round-up: GBP ahead on BoE buffer call and SNP's stance on indyref#2

Sterling enjoyed a minor rise on Tuesday on the back of Bank of England requiring lenders to beef up their cash buffer in case of bad debts.

27 Jun London close: Hike in banks' capital buffers hits shares

A stronger sterling weighed on the FTSE on Tuesday, as it emerged the Bank of England will force banks to further bolster their capital buffers to deal with bad debts .

27 Jun Ukraine struck by massive cyber attack, banks and government hit

A massive cyber attack has targeted much of Ukraine’s state infrastructure as IT systems in the country’s national bank and its largest airport shut down.

27 Jun Commodities: Crude futures rise on hopes of API data showing draw in US stores

Crude-oil futures are riding higher Tuesday as the market looks to industry data out later to show a draw in US stockpiles.

27 Jun Hardide receives Nadcap accreditation for its coatings

Advanced surface coating technology provider Hardide announced on Tuesday that Hardide Coatings had gained Nadcap accreditation for coatings.

27 Jun RedstoneConnect to install cabling at new Spurs stadium

Smart building and commercial spaces technology and services provider RedstoneConnect announced on Tuesday that it was awarded a contract to install an IT cabling infrastructure throughout Tottenham Hotspur's new 61,500 seat stadium.